1 | BACKGROUND
| Rising incidence of thyroid cancer is primarily an epidemic of diagnosis, not disease
Thyroid cancer is the most common malignancy of the endocrine system. The incidence of thyroid cancer has increased in much of the world, especially in developed nations. Vaccarella and colleagues described the rising incidence of thyroid cancer within high-income countries and noted dramatic increases in diagnosis in the United States, Italy, France, and other developed nations. By far the most dramatic increases in thyroid cancer incidence have been noted in South Korea, 1 where the incidence among women skyrocketed from 30 to 120 cases per 100, 000 women between the years 2003 and 2007. Recent literature, published over both the short and medium term, highlights the increasing incidence of thyroid cancer worldwide, and has linked this phenomenon to the wider use of diagnostic techniques such as ultrasound scans [2] [3] [4] [5] [6] [7] coupled with fine-needle aspiration of incidentally found small nodules. In the United States alone, new diagnoses of thyroid cancer have more than tripled in the last five decades. 8 While hypotheses explaining these rising trends have included environmental and genetic etiologies, a growing body of evidence has confirmed that the chief contribution to this rising incidence has been improvements in, and wider usage of, diagnostic modalities such as ultrasound. 3, 9 Indeed, a strong predictor of a region or country's incidence of thyroid cancer is the level of health care access and utilization of that region 10 and the degree to which the health system is privately funded.
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The increasing incidence is nearly entirely attributable to papillary thyroid carcinoma (PTC), observed to have the least aggressive behavior of the thyroid malignancies, and as primarily being of tumors less than 2 cm in size, consistent with increasing diagnosis of otherwise clinically occult disease. 2, 4, 8, 9 It has been estimated that 70%-80% of cases in the United States, and 50%-90% of cases in other developed nations are cases that would not have gone on to cause symptoms, harm, or death if never discovered-a phenomenon termed overdiagnosis.
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Despite the dramatic rise in incidence, the mortality rate (defined as the number of deaths from disease per 100,000 population) attributable to thyroid cancer has remained essentially static. 8 Recently,
analyses of national cancer registry data have uncovered a slight increase in thyroid cancer mortality-an increase in a subset of patients of 0.06 per 100,000 over two decades, in the context of a parallel increase in incidence of 8.2 per 100,000 12 suggesting that nearly all of the additional cases now being diagnosed do not ultimately prove to be lethal cancers.
| Large subclinical reservoir of thyroid cancer in healthy persons
Thyroid cancer is usually asymptomatic and has been commonly identified by large autopsy studies in patients with no evidence of known thyroid disease. The prevalence of occult thyroid cancers has been found to be as high as 30% in a classic study from Finland. 13, 14 Additional autopsy studies have placed the range of subclinical PTC in the range of 5%-30%, suggesting that it might be considered an essentially normal finding. Another way for estimating the prevalence of occult papillary carcinoma, in younger patients, has been to examine thyroid glands removed for benign disease. In these studies, the prevalence of small microcarcinomas has been shown to be up to 10.5%, with Pelizzo et al showing no evidence of disease in this occult patient group at follow-up greater than 5 years. 15 Similarly, a large Japanese screening study detected thyroid cancer in 3.6% of otherwise healthy Japanese women of which 85% were PTC sized 15 mm or smaller. 16 Again, this reported incidence was more than 1000 times higher than the reported prevalence of clinical thyroid carcinoma in Japanese women at the time. Taken together, these data indicate that the true incidence of subclinical thyroid carcinoma is much higher than the reported prevalence of clinical disease, suggesting that increasing use of diagnostic modalities would be likely to identify additional cases.
Occult carcinomas tend to be predominantly small PTCs 17, 18 and more specifically, microcarcinomas, or microPTC (defined as <1 cm in maximal diameter). MicroPTCs tend to be indolent in course with low rates of locoregional and distant metastases and have excellent disease-specific survival of nearly 100%. [19] [20] [21] However, many incidentally detected thyroid cancers are larger in size. When coupled with the understanding that close to none of the cases represented by the increasing incidence of PTC appear to result in a meaningful increase in the mortality rate in the United States, these identified trends can be reasonably attributed to increased sensitivity in diagnosing occult disease and the majority of these microPTCs are termed low risk. 8, 18 Thus, it is apparent that relatively small thyroid carcinomas are regularly present in otherwise healthy adults, and many will never adversely impact the well-being and life of their host. 
| Management of PTC has de-escalated
There is conflicting data within the literature regarding the need for low-intensity vs high-intensity treatment of papillary thyroid cancer.
In the past, strong advocacy has existed for aggressive treatment of PTC in an attempt to improve survival outcomes for patients with the disease. Unfortunately, there are no prospective randomized controlled trials comparing aggressive initial treatment to lesser intensity management; thus, decisions regarding intervention are often guided by retrospective and population-based registry data.
Certain trends in treatment and outcomes over the last few decades do favor conservative approaches to the treatment of PTC.
As noted previously, the advent of sensitive diagnostic imaging has led to an increase in the incidence of PTC over the last few decades, particularly small PTCs, without a resultant increase in mortality. 36 The investigators noted relatively low rates of tumor growth with 24 patients undergoing delayed thyroid surgery after commencing observation.
None of these patients had noted recurrence following surgery.
The results of the three trials revealed the overall safety of AS as a management option. Additionally, as noted by Miyauchi, patients who required surgical intervention after initiating AS for disease progression were able to avoid multiple operations and instead underwent one definitive procedure. 33 Most importantly though was the finding that even those who demonstrated disease progression during monitoring were able to undergo appropriate surgery with excellent oncologic outcomes.
In addition to demonstrating the safety of AS, these experiences with rapid growth and 38 patients [22%] with slow growth), while some cancers were noted to decrease in size (29 patients, 17%). 37 Further evaluation of these lesions among 1235 patients demonstrated low rates of growth and progression overall with respect to nodule size, appearance of new lymph node metastases, and progression to clinical disease. 34 However, young age (<40 years) was a notable independent predictor for nodule growth over time whereas older patients had very rare growth. 34, 38 Additional observations allowed for risk stratification of lesions based on location, relation to the tumor capsule, and histological appearance. Histological evaluation of confirmed PTC lesions revealed distinct growth patterns, specifically expansive growth and invasive growth. 39 Lesions with expansive growth demonstrated sharp margins between the tumor and surrounding gland parenchyma with an intact capsule, whereas lesions with an invasive growth pattern exhibited irregular margins, lack of tumor capsule, and infiltration into the thyroid parenchyma and had a higher risk of recurrence. 39 These data together allow for risk stratification of patients when considering AS.
| Active Surveillance in the United States
In 
| Instituting Active Surveillance
Due to the results of these new data, namely the safety of AS, the low rates of recurrence, the success of delayed surgery, and finally the lack of mortality associated with surveillance, the ATA guidelines were updated in 2015 to incorporate AS as an option within the management paradigm of PTC. 31 AS is therefore not considered an "experimental" treatment option, but rather one acceptable option within the standard of care for appropriately selected patients with low-risk thyroid cancers (Table 1) .
It is important to note that only one of the criteria outlined in Table 1 must be met when considering a patient for AS and surgery
Proportion of patients who demonstrate progression during active surveillance. 33, 34, 39 Proportion of patients who demonstrate nodule size enlargement (% total, defined as 3 mm size increase), novel nodal metastases, or convert to surgery during active surveillance. Japan, n = 1235; Korea, n = 360; United States, n = 291
can be offered at any point in the surveillance period. Additionally, Based on the 2015 guidelines update Brito et al proposed a framework for risk stratification of patients being considered for observation of PTC. 41 The approach encompasses evaluation of characteristics of the tumor, the patient, and the medical team ( Table 2) .
These criteria are then used to stratify patients into "ideal," Only one of the criteria listed above needs to be met to consider an active surveillance approach.
a Risk stratification scheme presented in Table 2 .
T A B L E 2 Brito categories for risk stratification of patients with papillary thyroid carcinoma when considering active surveillance among patients who underwent immediate surgery compared to AS. 33 Griffin et al performed a retrospective review of surgical patients eligible for AS to determine the number of surgical complications that could be avoided. In this study of 56 patients who met criteria for AS and all of whom underwent immediate surgery, 6 patients developed temporary hypoparathyroidism, 1 developed permanent hypoparathyroidism, 1 had temporary VCP, and 1 patient had permanent VCP. 43 In both series, the reported rates of complications were low, but in the context of patients who do not require surgery (both in the short and potentially long term) these complication rates could be considered unacceptably high, as they could be avoided altogether.
In addition to avoiding surgical risks specifically associated with Many patients may conclude that the risks of surgery, although low, outweigh the benefits, particularly given the evidence that equally curative operations can be performed at a later date should the thyroid cancer show signs of growth or progression. Other patients may come to the opposite conclusion, and decide that the risks of surgery are acceptable, and indeed preferable, to undergoing a process of AS. These conclusions are both reasonable. A thyroid surgeon is well suited to counsel a patient on the pros and cons, risks and sequelae, of either approach.
In addition to guiding the patient through this discussion, the physician must take into account the patient experience and must be aware of intrinsic biases and assumptions that may lead the physician to strongly favor one option over another. Despite the avoidance of surgical risk and lack of significant survival benefit, the potential psychological impact of living with cancer upon the patient may preclude the physician from viewing AS as a viable option. A study performed by Davies et al sought specifically to assess the experience of patients undergoing AS. Through a combination of patient surveys and interviews, they revealed that patients overall worry about cancer recurrence, metastases, and need for surgical intervention to a similar degree as patients who undergo surgery. 45 The proportion of patients who did not worry about their cancer outcomes steadily increased over the course of the surveillance period, and a large percentage of patients (83%) agreed that AS was the best management option for them. Additionally, and importantly, a large proportion of patients (77%) were not aware of AS as a treatment modality before it was offered to them. This study highlighted that patient experience with AS does not have a detrimental impact on psychological well-being and is in fact comparable to those patients who undergo surgical intervention. The worry that a patient may experience due to living with an active cancer, while understandable and not unreasonable, need not prohibit consideration of AS as a reasonable management option. Oftentimes, the explanation that surgery can be performed at a later date with equal effectiveness is useful in providing patients with the space to consider their options carefully.
Ongoing research seeks to further define the patient experience during the AS process and identify roadblocks to the implementation of this treatment modality. Furthermore, research is needed to identify clinical, radiographic, and molecular biomarkers to better risk-stratify tumors in terms of appropriateness for AS. Lastly, more prospective data are required to better define the optimal protocols for scans, clinical examination, and surgical intervention if needed.
| CONCLUSION
Active surveillance is a safe alternative to immediate surgery for many patients with low-risk papillary thyroid cancer. Patients and physicians weighing these options-observation or surgery-should understand that there is more than one "right answer" within the current standard of care. In this respect, thyroid surgeons are indispensable members of the multidisciplinary thyroid cancer team and best suited to guide patients through shared decision-making. Patients facing a new diagnosis of thyroid cancer will benefit from consultation with a surgeon, to discuss these options.
